CIK 0000315545 · Non-accelerated filer<br>Smaller reporting company
PROVECTUS BIOPHARMACEUTICALS, INC.
Sign in to watch- Ticker
- PVCT
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 900031917
- Phone
- (866) 594-5999
- Business address
- 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929
- Former names
- PROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC, SPM GROUP INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Lacey John III Director | Grant or award · Series D-1 Convertible Preferred Stock | +48,917 | 228,509 | ||
| 2026-06-30 | Bailey Webster Director | Grant or award · Series D-1 Convertible Preferred Stock | +48,917 | 207,535 | ||
| 2026-06-05 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-06-05 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +9,436 | 2,857,285 | ||
| 2026-05-28 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2026-05-23 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-05-23 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +32,089 | 2,847,849 | ||
| 2026-05-15 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-05-15 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +22,651 | 2,815,760 | ||
| 2026-05-07 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-05-07 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +18,876 | 2,793,109 | ||
| 2026-04-29 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-04-29 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +30,202 | 2,774,233 | ||
| 2026-04-04 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-04-04 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +33,977 | 2,744,031 | ||
| 2026-03-25 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2026-03-20 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2026-03-20 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +49,067 | 2,710,054 | ||
| 2026-03-12 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2026-03-05 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 |
Page 2 of 8 · 143 trades